2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1650 Shortened versus standard duration venetoclax in combination with hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis

Chiranjeevi Sainatham, MD, Harshitha Popuri Popuri2, Aravind Dilli Babu, MD3, Alexander Lund, MD4, Jacqueline Nguyen, DO5, Oscar Felipe Borja Montes, MD6, Forat Lutfi, MD7, Muhammad Junaid Tariq, MD8, Dina Khalaf, CLINICAL ASSOCIATE PROFESSOR9
1 University of Florida, Gainesville, Florida, United States
2 Texas Tech University, El Paso, Texas, United States
3 SUNY Downstate University, Brooklyn, New York, United States
4 University of Florida, Gainesville, Florida, United States
5 University of Florida, Gainesville, Florida, United States
6 University of Florida, Gainesville, Florida, United States
7 Orlando Health Cancer Center, Orlando, Florida, United States
8 University of Florida, Gainesville, Florida, United States
9 University of Florida, Gainesville, Florida, United States

Background: Venetoclax (VEN) plus hypomethylating has become a standard of care for newly diagnosed AML patients who are unfit for intensive chemotherapy. We commonly use a 21-28 day VEN schedule for the first cycle, but this is limited by prolonged cytopenias, cycle delays, dose reductions in further cycles, and abbreviated schedules are widely used in practice with more studies studying this approach in comparison to the standard 21-28 day schedule. We compared ≤14-day versus >14-day VEN schedules for response, survival, and hematologic toxicity.

Methods: We searched PubMed, Embase, Cochrane CENTRAL, and ASH/ASCO/EHA abstract archives for randomized and comparative observational studies of adults with newly diagnosed AML receiving VEN+HMA stratified by VEN days per cycle. Outcomes were complete remission (CR) alone, composite CR (CR+CRi), overall survival (OS), grade 3/4 neutropenia, febrile neutropenia, and grade 3/4 thrombocytopenia. Risk ratios (RR) were pooled by random-effects REML. For OS, log hazard ratios and variances were derived using the Tierney hierarchy (reported HR with CI where available; otherwise, estimated from median survival and the log-rank p-value) and pooled by generic inverse-variance random-effects. HR > 1 indicates a worse outcome with abbreviated dosing. Heterogeneity was assessed by I² and Cochran's Q, with prespecified leave-one-out sensitivity analysis. PROSPERO-registered.

Results: Eight comparative studies met eligibility criteria, including the randomized OPTI-AML trial. Composite CR was reported by all eight studies (≤14 d, n=450; >14 d, n=988) and did not differ between schedules, with a pooled RR of 0.97 (95% CI 0.87–1.08; p=0.56) and complete absence of heterogeneity (I²=0%, Q(7)=1.38, p=0.99). CR alone, available in three studies enrolling 507 patients, was likewise comparable at RR 0.98 (0.81–1.20; p=0.86), again with I²=0%.

Overall survival could be extracted from three studies comprising 362 patients (≤14 d n=147, >14 d n=215). The individual estimates were HR 1.17 (0.64–2.14), HR 0.92 (0.55–1.55, derived from median survival and the log-rank p-value), and HR 0.20 (0.06–0.67) in a 24-patient cohort. Pooling all three yielded an HR of 0.72 (0.34–1.54; p=0.40) with substantial heterogeneity (I²=70%, τ²=0.30, Q(2)=6.66, p=0.036) that was attributable entirely to the smallest study; on prespecified leave-one-out analysis excluding that cohort, the pooled HR moved to 1.02 (0.69–1.51; p=0.92), and heterogeneity resolved (I²=0%). Median OS in the two larger cohorts was 494 versus 578 days and 11.2 versus 10.3 months.

Every hematologic toxicity endpoint favored shortened dosing numerically without reaching statistical significance. Grade 3/4 neutropenia (three studies, n=331) gave an RR of 0.91 (0.73–1.13), febrile neutropenia (four studies, n=520) an RR of 0.92 (0.75–1.14), and grade 3/4 thrombocytopenia (two studies, n=259) an RR of 0.97 (0.77–1.23), with I²=0% throughout. Only two to four studies contributed to each toxicity endpoint, and all confidence intervals crossed unity.

 

Conclusions

Across 1438 patients, shortened dosing produced composite CR and CR that are statistically indistinguishable from standard dosing of VEN. OS showed no significant difference, but our analysis relies only on three studies, with one of the studies having only 24 patients (HR 0.2), and its removal completely changed the pooled result. This should be treated as hypothesis-generating rather than reassuring. High-grade neutropenia, thrombocytopenia, and febrile neutropenia were consistently lower with the shorter schedule, but the difference was not statistically significant, largely limited by fewer studies reporting these outcomes. Our systematic review limitations include the retrospective nature of most of the studies, likely chances that the sicker and frail patients are likely given shorter cycles (which biases the shortened arm towards worse survival), and that some data came from abstracts only.

Overall, shortened VEN dosing appears to be a reasonable individualized option in unfit patients, but the only randomized trial did not establish non-inferiority, and patients with certain mutation profiles may still benefit from longer exposure. Randomized trials powered for survival with prespecified genomic subgroups are needed.

Chiranjeevi Sainatham, MD: No relevant conflicts of interest to declare.